section name header

Pronunciation ⬇

be-TAX-oh-lol

Classifications ⬆ ⬇

Therapeutic Classification: antihypertensives

Pharmacologic Classification: beta blockers

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Blocks stimulation of beta1 (myocardial) adrenergic receptors. Does not usually affect beta2 (pulmonary, vascular, uterine) receptor sites.
Therapeutic effects:
  • Decreased BP and heart rate.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed after oral administration.

Distribution: Widely distributed.

Metabolism/Excretion: Mostly metabolized by the liver, 20% excreted unchanged by the kidneys.

Half-Life: 15–20 hr.

Time/Action Profile ⬆ ⬇

(antihypertensive effect)

ROUTEONSETPEAKDURATION
PO3–4 hr3–4 hr24 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: HF, BRADYCARDIA, hypotension, peripheral vasoconstriction, PULMONARY EDEMA

Derm: rashes

EENT: blurred vision, stuffy nose

Endo: hyperglycemia, hypoglycemia

GI: ↑liver enzymes, constipation, diarrhea, nausea, vomiting

GU: erectile dysfunction, ↓libido, urinary frequency

MS: arthralgia, back pain, joint pain

Neuro: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nightmares

Resp: bronchospasm, wheezing

Misc: drug-induced lupus syndrome

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Toxicity and Overdose:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Kerlone